טוען...
Targeting Interleukins for the Treatment of Inflammatory Bowel Disease—What Lies Beyond Anti-TNF Therapy?
Inflammatory bowel disease accounts for significant patient morbidity in the Western world. Several immunosuppressive therapies are available but are associated with potential significant adverse effects. In addition, there remains a cohort of patients with refractory or relapsing disease. Therefore...
שמור ב:
| הוצא לאור ב: | Inflamm Bowel Dis |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7667487/ https://ncbi.nlm.nih.gov/pubmed/24356385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/01.MIB.0000437616.37000.41 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|